Relationship between Interleukin-6 Expression with the Progressive and Severity of Ulcerative

Arif Nur Widodo; Neneng Ratnasari; Siti Nurdjanah

doi:10.22146/actainterna.50889

Relationship between Interleukin-6 Expression with the Progressive and Severity of Ulcerative

https://doi.org/10.22146/actainterna.50889

Arif Nur Widodo^(1*), Neneng Ratnasari⁽²⁾, Siti Nurdjanah⁽³⁾

(1)
(2)
(3)
(*) Corresponding Author

Abstract

Background. Based on international statistics, the incidence of Inflammatory Bowel Disease (IBD) is about 2.2-14.3 cases per 100.000 people per year for Ulcerative Colitis (UC). In Indonesia, there is no epidemiological study of IBD. To assess the degree of severity associated with the ulcerative colitis disease can be used a variety
of tools, including the Truelove Witts score which has sensitivity and specificity that high enough for UC in the phase of active disease. Interleukin-6 (IL-6) is a pro-inflammatory cytokine that plays a very important role in the self-defense mechanism and acts as an acute-phase protein. Serum levels of IL-6 and increased expression in the colonic mucosa of active IBD patients indicate the level of IBD disease activity.
Aims. The aim of the study was to determine the relationship between Interleukin-6 expression (IL-6) and the severity of UC disease using Truelove Witts classification.
Methods. This study used a cross-sectional method that analyzed the relationship between IL-6 expression and UC weighing based on Truelove Witts classification using colon tissue biopsy results from UC patients who met inclusion and exclusion criteria.
Results. Th ere were 26 subjects studied and performed an endoscopic analysis and anatomical pathology. Mean age of research subjects were 52.73 + 11.11 years with men's favored subjects (n = 15). Subjects were severe UC 16 (61.5%), moderate 7 (26.9%) and mild 3 (11.5%). More male subjects in mild UC, 12 vs. 3 and more female subjects in moderate-severe UC, 4 vs. 7 (p 0.032). Signifi cant diff erences in IL-6 expression in defecation were > 4 times/day, IL-6 300 (285-400) versus defecation < 4 times/day, IL-6 295 (212.1-340) p 0.039. Signifi cant diff erence in IL-6 expression between mild UC 295 (212.1-340) with moderate- severe UC 301.66 (235.57-400) with p value 0.032.
Conclusion. IL-6 expression in moderate-severe UC subjects was higher than mild UC subjects based on Truelove Witts criteria.
Keywords: Inflammatory Bowel Disease, Ulcerative Colitis, Truelove Witts classification, Interleukin-6.

Full Text:

PDF

References

Djojoningrat D.,2014. Inflammatory bowel disease. Dalam: Sudoyo A.W., Setiyohadi, B (Ed.): BuUC Ajar Ilmu Penyakit Dalam. Edisi ke-enam, hal 18141822. Interna Publishing Jakarta.

Talley NJ, Abreu MT, Achkar JP, Bernstein CN, Dubinsky MC, Hanauer SB, Kane SV

Sandborn WJ, Ullman TA, Moayyedi P. 2011. An Evidence-Based Systemic Review on Medical Therapies for Inflammatory Bowel Disease. Am J Gastroenterol; 106:S2– S25.

Judge, TA., Lichtenstein, GR. 2003.Inflammatory Bowel Disease in Friedman SL, McQuaid, KR., Grendell, JH editors.

Current Diagnosis and Treatment in Gastroenterology 2nd. McGraw-Hill. pp 108-30.

Barbara C., Taryn, D., Gioia, M.P., Yunsheng, M.A., Katherine, R., David, C., 2014. An anti-inflammatory diet as a treatment for inflammatory bowel disease: a case series report. Nutritional journal 13:5.

Satsangi, Silverberg, Colombel, 2006. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 55(6): 749–753.

Yang, C.H., Chen, X., Dai J., Zhang, Y., Ran, Z.H., Xiao, S.D., 2008. The Application of Montreal Classification in Inflammatory Bowel Disease. Chinese Internal Medicine 47(1):7-10

Dignass, A., Eliakim, R., Magro, F., Maaser, C., Chowers, Y., Geboes, K., Van Assche, G. (2012). Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: Definitions and diagnosis. Journal of Crohn’s and Colitis, 6(10), 965–990.

Ling J, Luo S, Lai J. 2015. Biological effects of interleukin-6: Clinical applications in autoimmune diseases and cancers. Biochemical Pharmacology. 97(1): 16-26

Alvarez, J.L.P., 2009. Interleukin 6 in the Physiopathology of Rheumatoid Arthritis. Journal Reumatol Clin, 5 (1): 34-9.

Mitsuyama K, Sata M, Tanikawa K. 1991. Significance of interleukin 6 in patients with inflammatory bowel disease. Gastroenterol Jpn. 26;20-28.

Hébuterne, X. J. Filippi, R. Al-Jaouni, S. Schneider, 2009. Nutritional consequences and nutrition therapy in Crohn’s disease. Gastroenté Urologie Clinique et Biologique, 33

Suppl 3, pp.S235-44.

DOI: https://doi.org/10.22146/actainterna.50889